[Oncology 2008].
Medizinische Klinik und Poliklinik III, Klinikum der LMU München, Standort Grosshadern, Marchioninistrasse 15, 81377 München. Joachim.Stemmler@med.uni-muenchen.de
H-J
HJ
Stemmler
V
V
Heinemann
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000008:administration & dosage; D000068258:Bevacizumab; D000068818:Cetuximab; D003131:Combined Modality Therapy; D018450:Disease Progression; D034261:Epothilones / Q000008:administration & dosage; D006801:Humans; D000077341:Lapatinib; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D000077544:Panitumumab; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D034261:Epothilones; D010671:Phenylurea Compounds; D011725:Pyridines; D011799:Quinazolines; D000077341:Lapatinib; D009536:Niacinamide; D000068258:Bevacizumab; D000077544:Panitumumab; D000077157:Sorafenib; C430592:ixabepilone; D000068818:Cetuximab